Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 5/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908466 | 0.76 | POLB (0.41) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15065075 | 0.74 | ALDH1A1 (0.36) | PIK3CAPRKAA2KDM4EALDH1A1HPGD | |
| SCHEMBL30845761 | 0.72 | MCHR1 (0.48) | KDM4EALDH1A1HPGDMETTL3MCHR1 | |
| SCHEMBL30526292 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1HPGDMETTL3MCHR1 | |
| SCHEMBL13791874 | 0.68 | KDM4E (0.51) | PIK3CAPRKAA2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL3885254 | 0.67 | KDM4E (0.50) | PIK3CAPRKAA2KDM4EALDH1A1HPGD | |
| SCHEMBL8342499 | 0.67 | ATR (0.41) | PIK3CAKDM4EALDH1A1NPC1MAPK3 | |
| SCHEMBL12723219 | 0.67 | MEN1 (0.45) | ALDH1A1NPC1MAPTSMN1; SMN2 | |
| SCHEMBL15066253 | 0.67 | IRAK4 (0.46) | MAPT | |
| SCHEMBL30078125 | 0.67 | IRAK4 (0.46) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PIK3CA 3340/4885PRKAA2 2066/4885KDM4E 1701/4885 |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | PIK3CA 3340/4885PRKAA2 2066/4885KDM4E 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.